Evidence map›Paper›PMID 29258566›Full record

ArticleJournal of experimental & clinical cancer research : CR2017

5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin.

Kaja Lund, Cathrine Elisabeth Olsen, Judith Jing Wen Wong, Petter Angell Olsen, Nina Therese Solberg, Anders Høgset, Stefan Krauss, Pål Kristian Selbo

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kaja LundUnit for Cell Signaling, Institute of Microbiology, Rikshospitalet, 0372, Oslo, Norway. Kaja.Lund@rr-research.no.
Cathrine Elisabeth OlsenDepartment of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, 0379, Oslo, Norway.
Judith Jing Wen WongDepartment of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, 0379, Oslo, Norway.
Petter Angell OlsenUnit for Cell Signaling, Institute of Microbiology, Rikshospitalet, 0372, Oslo, Norway.
Nina Therese SolbergUnit for Cell Signaling, Institute of Microbiology, Rikshospitalet, 0372, Oslo, Norway.
Anders HøgsetPCI Biotech AS, Ullernchaussèn 64, 0379, Oslo, Norway.
Stefan KraussUnit for Cell Signaling, Institute of Microbiology, Rikshospitalet, 0372, Oslo, Norway.
Pål Kristian SelboDepartment of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, 0379, Oslo, Norway. selbo@rr-research.no.
University of Oslo · NOOslo University Hospital · NOPCI Biotech (Norway) · NO

Funding

Helse Sør-Øst RHF 2016023Helse Sør-Øst RHF 2017068Kreftforeningen 33445The Norwegian Radium Hospital Research Foundation FU0803The Norwegian Radium Hospital Research Foundation SE1603
6 · The paper itself

Abstract

backgroundDevelopment of resistance to 5-fluorouracil (5-FU) is a major problem in treatment of various cancers including pancreatic cancer. In this study, we reveal important resistance mechanisms and photochemical strategies to overcome 5-FU resistance in pancreatic adenocarcinoma.

methods5-FU resistant (5-FUR), epithelial-to-mesenchymal-like sub-clones of the wild type pancreatic cancer cell line Panc03.27 were previously generated in our lab. We investigated the cytotoxic effect of the endosomal/lysosomal-localizing photosensitizer TPCS

resultsThe 5-FUR cell lines display hypersensitivity to PCT, which was linked to increased uptake of TPCS

conclusionOur findings suggested that autophagy is an important resistance mechanism against the chemotherapeutic drug 5-FU in pancreatic cancer cells, and that inhibition of the autophagy process, either by CQ or lysosomal photodamage, can contribute to increased sensitivity to 5-FU. For the first time, we demonstrate the promise of PCI-based targeting of CD105 in site-specific elimination of 5-FU resistant pancreatic cancer cells in vitro. In conclusion, PCI-based targeting of CD105 may represent a potent anticancer strategy and should be further evaluated in pre-clinical models.

Indexed as

AdenocarcinomaAntineoplastic AgentsAutophagyCell Line, TumorDrug Resistance, NeoplasmEndoglinEpithelial-Mesenchymal TransitionFluorouracilHumansImmunotoxinsPancreatic NeoplasmsPhotosensitizing AgentsPhototherapyPorphyrinsRibosome Inactivating Proteins, Type 1SaporinsAntineoplastic AgentsEndoglinENG protein, humanFluorouracilImmunotoxinsmeso-tetraphenyl chlorin disulphonatePhotosensitizing AgentsPorphyrinsRibosome Inactivating Proteins, Type 1Saporins5-FU resistanceAutophagyCD105EndoglinPancreatic cancerPhotochemical internalization

Identifiers

PMID29258566
PMCPMC5738190
OpenAlexW2776474038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.